Objective To observe the efficacy of venetoclax combined with hypomethylated drugs in the treatment of relapsed or refractory acute myeloid leukemia (AML).
Methods Clinical materials of 14 patients with relapsed or refractory AML in the Department of Hematology of the Northern Branch of Ruijin Hospital Affiliated to the Medical College of Shanghai Jiaotong University from January 2020 to August 2021 were analyzed retrospectively and followed up. Ten patients were treated with venetoclax and azacytidine, and the other four patients were treated with venetoclax and decitabine.
Results There were 5 cases with curative effect of complete remission (CR) or morphological CR with incomplete recovery of platelet count (CRi), 3 cases with partial remission (PR) and 6 cases with no remission (NR). Bone marrow suppression occurred in all the patients after treatment, and pulmonary infection was observed in 6 cases.
Conclusion The prognosis of patients with relapsed or refractory AML is poor. Venetoclax combined with hypomethylated drugs has a significant effect in some patients, which can achieve the CR result, and has better tolerance.
DownLoad: